Pellets - Vitamin E, Vitamin B6, Vitamin D3, Liposomal Zinc Bisglycinate Pellets, Vitamin B12, Vitamin A, IPC (Iron Polymaltose Complex), Folic Acid
Exhibitor Products
Information
Advanced Pelletized Nutraceuticals by WBCIL
WBCIL’s pellets are advanced, multi-particulate dosage forms developed using precision pelletization technology. This ensures uniform particle size, excellent flow properties, and reliable dissolution performance. These pellets support immediate, sustained, controlled, and delayed-release formulations, offering high bioavailability, consistent drug release, and improved patient compliance.
Key Benefits of WBCIL’s Pellet Technology:
• Sustained Release Control: Active ingredients are released gradually over time.
• Dose Flexibility & Uniformity: Suitable for capsules, tablets, oral suspensions, etc.
• GI Safety & Reduced Irritation: Minimizes local high concentrations, ideal for acid-sensitive APIs.
• Targeted Delivery: Can be engineered for site-specific drug delivery in the GI tract.
• Improved Patient Compliance: Small size, taste-masked, and dosing intervals of 12-24 hours.
Product Offerings:
Liposomal Pellets:
• Liposomal Iron 7%
• Liposomal Calcium 20%
• Liposomal Magnesium 15%
• Liposomal Vitamin C 35%
• Liposomal Zinc 15%
• Liposomal Vitamin K2 0.5%
• Liposomal Glutathione 35%
• Liposomal Alpha Lipoic Acid 50%
Newly Developed Pellets:
• Aceclofenac 90%
• Amlodipine 5%
• Aspirin 53%
• Cyclobenzaprine HCl 50%
• Domperidone 7.5%
• Ibuprofen 40%
• Pancreatin 80%
• Pantoprazole 50%
• Simethicone 24%
Other Pellets:
• Ferrous Ascorbate 7%
• Ferrous Bisglycinate 15%
• Ferrous Glycine Sulphate 24%
• Iron Polymaltose Complex 20%
• IPC Blended (with Folic Acid)
• Calcium Citrate Malate 20%
• L-Methylfolate 1%
• Liposomal Methylcobalamin 500 mcg
• Sodium Butyrate 90%
WBCIL’s liposomal pellets represent a breakthrough in controlled drug release, enhancing protection for sensitive APIs and improving absorption for more effective therapeutic outcomes. We also offer custom development for tailored formulations to meet specific regulatory and release profile requirements.
